Erasca Inc

NASDAQ:ERASUnited States

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.

Contact Information

Headquarters

10835 Road To The Cure, Suite 140SAN DIEGO, CA, United States 92121-1130

Phone

858-465-6511

Fax

302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder

Jonathan Lim

Chief Financial Officer and Chief Business Officer

David Chacko

Director, Chair of Research and Development

Michael Varney

General Counsel, Corporate Secretary

Ebun Garner

Chief Medical Officer

Shannon Morris